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The goal of this study is to investigate the value of tau phosphorylated at threonine
181 (P-tau181P) in the Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarker panel
for differential dementia diagnosis in autopsy confirmed AD and non-AD patients. The
study population consisted of 140 autopsy confirmed AD and 77 autopsy confirmed
non-AD dementia patients. CSF concentrations of amyloid-β peptide of 42 amino acids
(Aβ1–42), total tau protein (T-tau), and P-tau181P were determined with single analyte
ELISA-kits (INNOTEST®, Fujirebio, Ghent, Belgium). Diagnostic accuracy was assessed
through receiver operating characteristic (ROC) curve analyses to obtain area under
the curve (AUC) values and to define optimal cutoff values to discriminate AD from
pooled and individual non-AD groups. ROC curve analyses were only performed on
biomarkers and ratios that differed significantly between the groups. Pairwise comparison
of AUC values was performed by means of DeLong tests. The Aβ1–42/P-tau181P ratio
(AUC=0.770) performed significantly better than Aβ1–42 (AUC=0.677, P=0.004), T-
tau (AUC=0.592, P<0.001), and Aβ1–42/T-tau (AUC=0.678, P=0.001), while P-
tau181P (AUC=0.720) performed significantly better than T-tau (AUC=0.592, P<0.001)
to discriminate between AD and the pooled non-AD group. When comparing AD
and the individual non-AD diagnoses, Aβ1–42/P-tau181P (AUC=0.894) discriminated AD
from frontotemporal dementia significantly better than Aβ1–42 (AUC=0.776, P=0.020)
and T-tau (AUC=0.746, P=0.004), while P-tau181P/T-tau (AUC=0.958) significantly
improved the differentiation between AD and Creutzfeldt-Jakob disease as compared to
Aβ1–42 (AUC=0.688, P=0.004), T-tau (AUC=0.874, P=0.040), and Aβ1–42/P-tau181P
(AUC=0.760,P=0.003). In conclusion, this study demonstrates P-tau181P is an essential
component of the AD CSF biomarker panel, and combined assessment of Aβ1–42, T-
tau, and P-tau181P renders, to present date, the highest diagnostic power to discriminate
between AD and non-AD dementias.
Keywords: Alzheimer’s disease, dementia, differential diagnosis, biomarkers, cerebrospinal fluid,
neuropathology, tau
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Introduction
The clinical diagnosis of Alzheimer’s disease (AD) is mainly based
on the exclusion of other diseases (1). Relative to autopsy confir-
mation, the clinical diagnostic criteria of AD (1) reach on average
81% sensitivity and 70% specificity (2). However, these figures
mostly originate from specialized clinical centers and from diag-
noses based on follow-up periods of several years. In the earliest
stages of the disease and when the diagnostic work-up is per-
formed in non-specialized centers, far lower diagnostic accuracy
can be expected. Diagnosis of definite AD can therefore only be
made through postmortem pathological examination of the brain.
Analyzing cerebrospinal fluid (CSF) levels of amyloid-β pep-
tide of 42 amino acids (Aβ1–42), total tau protein (T-tau) and tau
phosphorylated at threonine 181 (P-tau181P) increases diagnos-
tic certainty for AD (3). Based on autopsy confirmation, it was
shown that in the majority of patients with a clinically ambiguous
diagnosis (when the clinical diagnostic work-up was not able to
discriminate between AD and a non-AD dementia), a correct
diagnosis would have been established in 82% by using these CSF
biomarkers, indicating that CSF biomarkers may have a partic-
ular added diagnostic value in patients with ambiguous clinical
diagnoses (4).
Compared to controls, decreased Aβ1–42 and increased T-tau
and/or P-tau181P concentrations are found in AD. However, when
compared to non-AD dementias, the differences are less obvious
as the concentrations in patients with non-AD dementias are gen-
erally intermediate compared to those found between controls and
ADpatients, thus pointing to an overlap betweenAD and non-AD
patients, especially in dementia with Lewy bodies (DLB) and to a
lesser extent in frontotemporal dementia (FTD), vascular demen-
tia (VaD), and Creutzfeldt-Jakob’s disease (CJD) (5). This overlap
may partly be explained by the presence of mixed pathologies as
well as the low sensitivity and specificity of the clinical diagnosis
as most biomarker studies rely on clinically diagnosed patients.
The goal of this study is to investigate the value of P-tau181P in
the AD CSF biomarker panel for differential dementia diagnosis
in autopsy confirmed AD and non-AD patients.
Materials and Methods
Study Population
In brief, the study population consisted of 140 and 77 CSF samples
from dementia patients with pathologically confirmed diagnoses
of AD and non-AD, respectively. All CSF samples were selected
from the Biobank, Institute Born-Bunge, Antwerp, Belgium. Sam-
ples from 173 dementia patients were collected in the Memory
Clinic of the Hospital Network Antwerp (ZNA, Antwerp, Bel-
gium) between January 1992 andMay 2008, whereas samples from
44 dementia patients were collected in referring centers between
April 1992 and May 2005.
The study was approved by the local ethics committee (CME
Middelheim) and all subjects gave written informed consent.
Pathological Criteria
All pathological diagnoses were established according to standard
neuropathological criteria by the same neuropathologist (Jean-
Jacques Martin). Although the neuropathologist was blinded for
the CSF biomarker data, he had access to all neuroimaging data
and the clinical files of the patients included. For the diagnosis
of AD, VaD (n= 18), and DLB (n= 24), the neuropathological
criteria of Montine et al. (6) were applied. FTD (n= 17) was
neuropathologically diagnosed according to the Cairns criteria (7)
andMackenzie criteria (8, 9). CJD (n= 13) was diagnosed accord-
ing to the criteria of Markesbery (10). Mixed dementia (MXD)
was diagnosed when the patient fulfilled the neuropathological
criteria of AD in combination with minor pathology suggestive
of cerebrovascular disease (n= 12), DLB (n= 1), or Parkinson’s
disease (n= 1). For statistical analyses, the MXD group (n= 14)
was pooled with the AD group. The pooled non-AD group
furthermore consisted of few patients with progressive nuclear
palsy (n= 3), spinocerebellar ataxia (n= 1), and normal pressure
hydrocephalus combined with VaD (n= 1). Neuropathology was
performed on the right hemisphere of the brain.
CSF Analyses
All subjects underwent a lumbar puncture (LP) in order to collect
CSF. LP was performed between the intervertebral space L3/L4
or L4/L5 (11). CSF was sampled according to a standard protocol
(12). All samples were stored in polypropylene vials to avoid
adsorption of Aβ to the wall of the vial. The samples were frozen
in liquid nitrogen and stored at 80°C until analysis.
CSF concentrations of Aβ1–42, T-tau, and P-tau181P were
determined with commercially available single analyte ELISA-
kits (respectively, INNOTEST® β-AMYLOID(1–42), INNOTEST®
hTAU-Ag, and INNOTEST® PHOSPHO-TAU(181P); Fujirebio,
Ghent, Belgium). A complete description of the CSF analysis has
been published previously (13).
Statistical Analyses
Statistical analyses were performed using SPSS 20. As most vari-
ables were not normally distributed, non-parametric tests were
used. To compare gender distribution between the groups, a Chi-
square test was performed. Subsequently, Mann–Whitney U tests
were performed to compare clinical and biomarker data between
the groups. Receiver operating characteristic (ROC) curve anal-
yses were used to obtain area under the curve (AUC) values
and to define optimal cutoff values to discriminate AD from the
pooled and individual non-AD groups. ROC curve analyses were
only performed on biomarkers and ratios that were significantly
different (P< 0.05), based on the Mann–Whitney U tests. The
cutoff values were determined by calculating the maximal sum
of sensitivity and specificity (i.e., maximizing the Youden index).
In order to pairwise compare AUC values, DeLong tests were
performed using the pROC package (14) in the statistical software
package R (R Core Team).
Systematic Review
To be able to compare the results of this study, a systematic
review on the diagnostic accuracy of P-tau181P for differential
dementia diagnosis was performed. A PubMed search (until May
2015) was performed using the following terms: (Cerebrospinal
fluid OR CSF) AND diagnos* AND (Alzheimer* OR AD OR
dementia) AND (tauORbeta amyloidOR abeta) AND (sensitivity
OR specificity). Only publications in the English language were
Frontiers in Neurology | www.frontiersin.org June 2015 | Volume 6 | Article 1382
Struyfs et al. P-tau for differential dementia diagnosis
TABLE 1 | Demographic, clinical, and biomarker data of the study
population.
AD Non-AD P-value
N (M/F) 140 (71/69) 77 (45/32) 0.275
Age at sampling
(years)
76 (71–85) 72 (65–76) 0.001
MMSE (/30) 14 (9–19) (n= 98) 16 (9–21) (n=51) 0.228
Years between
sampling and death
0.0 (0.0–2.5) 0.0 (0.0–2.0) 0.452
Aβ1–42 (pg/mL) 361 (264–485) 514 (369–695) <0.001
T-tau (pg/mL) 581 (335–872) 379 (242–787) 0.025
P-tau181P (pg/mL) 73.2 (51.6–100.0) 45.0 (31.9–65.9) <0.001
Aβ1–42/T-tau 0.682 (0.399–1.100) 1.273 (0.719–2.257) <0.001
Aβ1–42/P-tau181P 4.982 (3.174–7.802) 10.535 (6.522–16.711) <0.001
P-tau181P/T-tau 0.138 (0.113–0.171) 0.141 (0.090–0.158) 0.094
All data are median values with 25th and 75th quartiles between brackets, except for N.
To compare gender distribution between the groups, a Chi-square test was performed,
while Mann–Whitney U tests were used to compare clinical and biomarker data between
the groups.
AD, Alzheimer’s disease; non-AD, dementia not due to Alzheimer’s disease; MMSE,
mini-mental state examination; Aβ1–42, amyloid-β peptide of 42 amino acids; T-tau, total
tau-protein; P-tau181P, tau phosphorylated at threonine 181.
Bold values show statistically significant P-values (P< 0.05).
evaluated. Subsequently, relevant publications were searched for
in reference lists. Publications were included when: (a) their aim
was to improve the diagnostic accuracy of diagnosis of demen-
tia by means of CSF biomarkers, (b) AD patients and pooled
non-AD patients or patients with DLB, FTD, VaD and/or CJD
were included, (c) P-tau181P together with Aβ1–42 and/or T-tau
was measured in CSF, and (d) diagnostic accuracy values were
reported (AUC, sensitivity, and/or specificity). Publications com-
paring only AD to healthy control subjects were not considered.
Results
Table 1 shows the demographic, clinical, and biomarker data of
the studied population. TheADandnon-ADgroupswere not age-
matched. However, based on co-variate analyses, confounding
effects of age on differences in biomarker concentrations were
excluded. Therefore, no corrections for age were included in the
subsequent analyses. Boxplots of the individual biomarkers and
ratios are presented in Figure 1.
The diagnostic powers to discriminate between AD and non-
AD of the individual biomarkers and ratios that were significantly
different are shown in Table 2. Based on the DeLong tests
FIGURE 1 | Boxplots of the individual biomarkers and ratios,
comparing AD and non-AD. (A) Aβ1–42; (B) T-tau; (C) P-tau181P;
(D) Aβ1–42/T-tau; (E) Aβ1–42/P-tau181P; (F) P-tau181P/T-tau. AD, Alzheimer’s
disease; non-AD, dementia not due to Alzheimer’s disease; Aβ1–42, amyloid-β
peptide of 42 amino acids; T-tau, total tau-protein; P-tau181P, tau
phosphorylated at threonine 181.
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TABLE 2 |Diagnostic power of the significantly different individual biomark-
ers and ratios to discriminate between AD and non-AD, measured by ROC
curve analyses.
AD vs. non-AD AUC 95% CI Cutoff Sens (%) Spec (%)
Aβ1–42 0.677 0.597–0.757 500.27 79.3 53.2
T-tau 0.592 0.508–0.675 472.35 62.1 63.6
P-tau181P 0.720 0.648–0.792 50.35 77.9 61.0
Aβ1–42/T-tau 0.678 0.601–0.755 1.08 75.0 57.1
Aβ1–42/P-tau181P 0.770 0.703–0.837 9.11 82.9 59.7
AD, Alzheimer’s disease; non-AD, dementia not due to Alzheimer’s disease; AUC, area
under the curve; CI, confidence interval; sens, sensitivity; spec, specificity; Aβ1–42,
amyloid-β peptide of 42 amino acids; T-tau, total tau-protein; P-tau181P, tau phospho-
rylated at threonine 181.
TABLE 3 |P values of pairwise comparisons of AUC values of the ROC curve
analyses to discriminate between AD and non-AD, using DeLong tests.
P-tau181P Aβ1–42/P-tau181P
Aβ1–42 0.450 0.004
T-tau <0.001 <0.001
Aβ1–42/T-tau 0.290 0.001
Aβ1–42/P-tau181P 0.100 NA
Aβ1–42, amyloid-β peptide of 42 amino acids; T-tau, total tau-protein; P-tau181P, tau
phosphorylated at threonine 181; NA, not applicable.
Bold values show statistically significant P-values (P< 0.05).
TABLE 4 | P values of pairwise comparisons of the individual biomarkers
and ratios, measured by Mann–Whitney U tests.
AD vs. FTD AD vs. DLB AD vs. CJD AD vs. VaD
Aβ1–42 <0.001 0.068 0.025 0.078
T-tau 0.001 0.051 <0.001 0.019
P-tau181P <0.001 0.011 0.081 0.001
Aβ1–42/T-tau <0.001 0.008 0.054 0.010
Aβ1–42/P-tau181P <0.001 0.002 0.002 0.003
P-tau181P/T-tau 0.096 0.232 <0.001 0.932
AD, Alzheimer’s disease; FTD, frontotemporal dementia; DLB, dementia with Lewy bodies;
CJD, Creutzfeldt-Jakob disease; VaD, vascular dementia; Aβ1–42, amyloid-β peptide of 42
amino acids; T-tau, total tau-protein; P-tau181P, tau phosphorylated at threonine 181.
Bold values show statistically significant P-values (P< 0.05).
(Table 3), the AUC of the Aβ1–42/P-tau181P ratio was significantly
different from those of Aβ1–42, T-tau, and Aβ1–42/T-tau, while the
AUC of P-tau181P differed significantly from the AUC of T-tau.
When comparing AD and the different non-AD diagnoses, the
Aβ1–42/P-tau181P ratio was significantly different in every differ-
ential diagnosis (Table 4). This also held true for P-tau181P, except
for AD vs. CJD. On the other hand, P-tau181P/T-tau was found to
be significantly different when comparing AD to CJD.
The diagnostic powers to discriminate between AD and the
different non-AD diagnoses of the individual biomarkers and
ratios that differed significantly are shown inTable 5. Based on the
DeLong tests (Table 6), the Aβ1–42/P-tau181P ratio performed sig-
nificantly better than Aβ1–42 and T-tau to discriminate AD from
FTD, while the AUC of P-tau181P/T-tau was significantly better
than those of Aβ1–42, T-tau, and Aβ1–42/P-tau181P to differentiate
between AD and CJD.
The results of the systematic review are summarized in Table
S1 in Supplementary Material. Only results comparing AD to
non-AD, FTD, DLB, CJD, and/or VaD were included in this table.
TABLE 5 |Diagnostic power of the significantly different individual biomark-
ers and ratios to discriminate between AD and individual non-AD diag-
noses, measured by ROC curve analyses.
AUC 95% CI Cutoff Sens (%) Spec (%)
AD vs. FTD
Aβ1–42 0.776 0.652–0.900 385.31 57.1 88.2
T-tau 0.746 0.654–0.838 423.00 67.9 82.4
P-tau181P 0.810 0.710–0.910 47.25 81.4 76.5
Aβ1–42/T-tau 0.863 0.794–0.931 0.97 70.1 94.1
Aβ1–42/P-tau181P 0.894 0.823–0.965 9.77 86.4 82.4
AD vs. DLB
P-tau181P 0.664 0.539–0.788 59.05 65.7 70.8
Aβ1–42/T-tau 0.670 0.539–0.802 0.80 60.7 75.0
Aβ1–42/P-tau181P 0.694 0.565–0.824 8.46 80.0 58.3
AD vs. CJD
Aβ1–42 0.688 0.521–0.855 440.12 66.4 69.2
T-tau 0.874 0.775–0.973 >1200 84.3 92.3
Aβ1–42/P-tau181P 0.760 0.634–0.886 6.84 67.9 84.6
P-tau181P/T-tau 0.958 0.925–0.991 0.1030 84.3 100.0
AD vs. VaD
T-tau 0.670 0.534–0.807 467.93 62.1 72.2
P-tau181P 0.733 0.599–0.867 49.85 78.6 66.7
Aβ1–42/T-tau 0.687 0.569–0.804 0.72 56.4 77.8
Aβ1–42/P-tau181P 0.718 0.598–0.838 5.30 55.7 77.8
AD, Alzheimer’s disease; FTD, frontotemporal dementia; DLB, dementia with Lewy bodies;
CJD, Creutzfeldt-Jakob disease; VaD, vascular dementia; AUC, area under the curve; CI,
confidence interval; sens, sensitivity; spec, specificity; Aβ1–42, amyloid-β peptide of 42
amino acids; T-tau, total tau-protein; P-tau181P, tau phosphorylated at threonine 181.
TABLE 6 |P values of pairwise comparisons of AUC values of the ROC curve
analyses to discriminate between AD and individual non-AD diagnoses,
using DeLong tests.
P-tau181P Aβ1–42/P-tau181P P-tau181P/T-tau
AD vs. FTD
Aβ1–42 0.700 0.020 NA
T-tau 0.120 0.004 NA
Aβ1–42/T-tau 0.280 0.280 NA
AD vs. DLB
Aβ1–42/T-tau 0.890 0.360 NA
AD vs. CJD
Aβ1–42 NA 0.327 0.004
T-tau NA 0.220 0.040
Aβ1–42/P-tau181P NA NA 0.003
AD vs. VaD
T-tau 0.370 0.600 NA
Aβ1–42/T-tau 0.600 0.610 NA
AD, Alzheimer’s disease; FTD, frontotemporal dementia; DLB, dementia with Lewy bodies;
CJD, Creutzfeldt-Jakob disease; VaD, vascular dementia; Aβ1–42, amyloid-β peptide of 42
amino acids; T-tau, total tau-protein; P-tau181P, tau phosphorylated at threonine 181; NA,
not applicable.
Bold values show statistically significant P-values (P<0.05).
Discussion
The goal of this study was to investigate the value of P-tau181P
in the AD biomarker panel for differential dementia diagno-
sis. First of all, the ratio of Aβ1–42/P-tau181P was shown to
have a significantly higher diagnostic power than Aβ1–42, T-tau,
and the Aβ1–42/T-tau ratio, while P-tau181P was found to per-
form significantly better than T-tau to discriminate between AD
and non-AD dementia. This clearly signifies the importance of
P-tau181P in the biomarker panel for differential dementia diag-
nosis. Our results are in line with previously reported findings of
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(combinations with) P-tau181P having most power to discriminate
between AD and non-AD dementias (12, 15–29).
However, in contrast to former studies performed in clinically
diagnosed AD and pooled non-AD dementia patients (15, 21,
22, 26–28), the AUC, sensitivity, and specificity of neither
P-tau181P nor Aβ1–42/P-tau181P reached the minimal level of 0.80,
as established by the Consensus Report of the Working Group on
Molecular and Biochemical Markers of AD (30). This is probably
not due to the accuracy of the diagnoses used in this study, as
autopsy confirmation was used. A possible explanation of the
discrepancy in accuracy levels between this study and former
studies could be the composition of the non-ADgroups. As shown
in this study, the accuracy levels of, for example, AD vs. FTD are
substantially higher than those of AD vs. DLB. Therefore, if a non-
AD group is primarily composed of FTD patients, the AUC levels
may be higher than when DLB patients prevail in the non-AD
group.
When focusing on the discrimination between AD and FTD,
our results showed that the diagnostic power of Aβ1–42/P-tau181P
was significantly higher than those of Aβ1–42 and T-tau. These
results confirm earlier studies performed in clinically diagnosed
AD and FTD patients (16, 17, 24, 25, 29).
With regard to the differentiation between AD and CJD, the
diagnostic power of P-tau181P/T-tau was significantly higher than
those of Aβ1–42, T-tau, and Aβ1–42/P-tau181P. Our results confirm
those of former studies performed in clinically diagnosed AD and
CJD patients, and partly performed in autopsy confirmed cases
(31–34).
In these latter two comparisons with individual non-AD
groups, the AUCs did reach the minimal level of 0.80. This indi-
cates that the pathophysiological variability in the pooled non-AD
group lowers the diagnostic accuracy of the CSF biomarkers.
It should be noted that the ratios and other combinations
of the AD CSF biomarkers should be used with care. Due to
(pre-)analytical issues (35), concentrations differ exceedingly
between laboratories. External quality controls and reference
material might be able to reduce this variability, which would
enable the general use of the same cutoff that was validated in
a multicenter setting. At this moment, cutoffs for individual
biomarkers as well as ratios and other combinations should
be validated in-house before they can be used in clinical
practice (36, 37).
In order to further increase diagnostic accuracy, other biomark-
ers should be included in the biomarker panel in the future.
Examples of possible fluid biomarkers for features of Aβ process-
ing in AD are β-site APP cleaving enzyme-1 (BACE1) activity
(38–44), soluble amyloid precursor protein (sAPP) α and β (42,
44–51), andAβ oligomers (52–60). Some fluid biomarkers that are
still being investigated seem more specific for non-AD dementias
and could also increase diagnostic accuracy when added to the
biomarker panel. Examples of possible such non-AD biomark-
ers are TAR DNA-binding protein 43 (TDP-43) (61–63), TPD-
43 phosphorylated at S409 (pTDP-43) (63), and progranulin
(64–66) for FTD, α-synuclein (67–71) and neurosin (72) for
DLB, metalloproteinases-9 for VaD (73, 74), and total CSF
prion protein for CJD (75). For reviews on these biomark-
ers, see Ref. (76–80). Most of these biomarkers need exten-
sive validation as well as validated ready-to-use analytical meth-
ods before they can be used in combination with Aβ1–42, T-
tau, and P-tau181P for differential dementia diagnosis in clinical
practice.
Another highly promising approach is combining fluid
biomarkers and imaging, such as magnetic resonance imaging
(MRI) and positron emission tomography (PET) imaging. Several
studies have shown that combinations of fluid and imaging
biomarkers render higher diagnostic power than these modalities
alone (81–85).
In conclusion, this study demonstrates P-tau181P is a funda-
mental component of the AD biomarker panel and the combined
assessment of Aβ1–42, T-tau, and P-tau181P renders, to present date,
the highest diagnostic power to discriminate between AD and
non-AD dementias. New biomarkers more specifically targeted at
non-AD dementia pathology should further increase diagnostic
power in the future.
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